Posted by Michael Wonder on 17 Jun 2021
Applied Therapeutics granted fast track designation by FDA for AT-007 for galactosaemia
17 June 2021 - Applied Therapeutics today announced that the U.S. FDA has granted fast track designation to AT-007 for the treatment of galactosaemia, a rare metabolic disease.
AT-007 is the Company’s central nervous system-penetrant aldose reductase inhibitor in development for multiple rare metabolic disorders, including galactosaemia, SORD and PMM2-CDG.
